Compare DSY & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | FGEN |
|---|---|---|
| Founded | 2020 | 1993 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 35.6M |
| IPO Year | N/A | 2014 |
| Metric | DSY | FGEN |
|---|---|---|
| Price | $0.35 | $8.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | ★ 124.0K | 32.3K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.37 | N/A |
| EPS | 0.01 | ★ 53.38 |
| Revenue | $7,323,356.00 | ★ $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.97 | ★ $0.17 |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $0.32 | $4.85 |
| 52 Week High | $7.33 | $21.94 |
| Indicator | DSY | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 19.08 | 49.39 |
| Support Level | $0.32 | $7.99 |
| Resistance Level | $0.43 | $8.55 |
| Average True Range (ATR) | 0.02 | 0.36 |
| MACD | 0.00 | 0.14 |
| Stochastic Oscillator | 21.87 | 94.20 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.